Düsseldorf, Tokyo and New York – October 22, 2024 – Asahi Kasei Medical introduced the PlanovaTM FG1, a next-generation viral elimination filter with increased flow for the production of biotherapeutics.
Asahi Kasei Medical’s bioprocess business includes biosafety testing services, biopharmaceutical CDMO operations, and PlanovaTM virus removal filters and equipment utilized in the production of biotherapeutic products such biopharmaceuticals and plasma derivatives. It is one of the companies of the Asahi Kasei Group that will propel its future expansion. With the introduction of Planova™ BioEX hydrophilic PVDF hollow-fiber membrane filters in 2009 and Planova™ S20N next-generation cellulose hollow-fiber membrane filters in 2022, the company, which has been in business since 1989, increased the range of products it offers to meet global standards for the viral safety of biotherapeutics.
PlanovaTM FG1, which was created to increase efficiency in the production of biopharmaceuticals, has excellent performance in terms of filtration speed and virus elimination resilience. Because of its high flux, which is around seven times that of Planova™ BioEX, viral filtering time can be decreased, and when the filtration process is stopped, there is a lower chance of virus breakthrough. Even without a prefilter to remove aggregates, customer evaluation during the PlanovaTM FG1 development stage proved strong protein filtration and virus elimination performance under a variety of situations using multiple solutions.
In order to help its clients effectively scale up their processes, Asahi Kasei Medical will gradually expand the product selection with new filters with greater surface areas after the October 2024 commencement of mass production and distribution of smaller filters of PlanovaTM FG1. Asahi Kasei Medical will strengthen the Planova™ brand’s position among biopharmaceutical manufacturers and help make pharmaceutical production safer and more effective by incorporating Planova™ FG1 into its extensive product portfolio. Asahi Kasei Medical President Ken Shinomiya stated, “Asahi Kasei Medical is excited to introduce the Planova™ FG1 next-generation virus removal filter.” “With our extensive and expanding product line, we look forward to continuing to assist biopharmaceutical firms in safely
